Oncolytics Biotech Inc. - ADR
$0.80
$-0.02
(-2.07%)
As on 12-Jun-2026 16:00EDT
Market cap
$96 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1055
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-7.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.3
-
Face value
--
-
Shares outstanding
119,354,067
10 Years Aggregate
CFO
$-190.21 Mln
EBITDA
$-202.28 Mln
Net Profit
$-224.13 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Oncolytics Biotech - ADR
| -8.1 | -11.1 | -20.5 | 40.2 | -19.7 | -23.0 | -14.2 |
|
BSE Sensex*
| -9.9 | 1.1 | 2.3 | -6.0 | 6.4 | 7.7 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Oncolytics Biotech - ADR
| -4.4 | -17.2 | 17.3 | -41.6 | -50.0 | 163.0 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Oncolytics Biotech - ADR
|
0.8 | 95.8 | 0.0 | -35.5 | -- | -- | -- | 1,055.0 |
| 61.0 | 598.1 | 0.0 | -27.5 | -- | -14.1 | -- | 2.7 |
Shareholding Pattern
View DetailsAbout Oncolytics Biotech - ADR
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the... treatment of gastrointestinal ("GI") tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California. Read more
-
President, CEO & Director
Dr. Matthew C. Coffey M.B.A., Ph.D.
-
President, CEO & Director
Dr. Matthew C. Coffey M.B.A., Ph.D.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Oncolytics Biotech - ADR
What is the current share price of Oncolytics Biotech Inc - ADR Today?
The share price of Oncolytics Biotech Inc - ADR is $0.80 (NASDAQ) as of 12-Jun-2026 16:00 EDT. Oncolytics Biotech Inc - ADR has given a return of -19.69% in the last 3 years.
What is the current PB & PE ratio of Oncolytics Biotech Inc - ADR?
Since, TTM earnings of Oncolytics Biotech Inc - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.12
|
-16.07
|
|
2024
|
-2.19
|
11.62
|
|
2023
|
-4.84
|
3.61
|
|
2022
|
-5.09
|
3.66
|
|
2021
|
-3.64
|
2.12
|
What is the 52 Week High and Low of Oncolytics Biotech Inc - ADR?
The 52-week high and low of Oncolytics Biotech Inc - ADR are Rs 1.51 and Rs 0.49 as of 15-Jun-2026.
What is the market cap of Oncolytics Biotech Inc - ADR?
Oncolytics Biotech Inc - ADR has a market capitalisation of $ 96 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Oncolytics Biotech Inc - ADR?
Before investing in Oncolytics Biotech Inc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.